Semax
Synthetic ACTH (4-7) analog studied in neuroprotection and BDNF-pathway research.
Synthetic ACTH (4-7) analog studied in neuroprotection and BDNF-pathway research.
The primary literature on this compound includes Ashmarin et al., Patol Fiziol Eksp Ter (1995). The references below link directly to the published record.
Every lot is synthesized in the USA, verified by HPLC, and ships with its Certificate of Analysis. It is supplied strictly for laboratory research use.
Research use only. Everything on this page describes laboratory research. This compound is supplied strictly for in-vitro research use; it is not approved by the FDA for human or veterinary use, and nothing here is a protocol or a recommendation.
Published research
- The efficacy of semax in the treatment of patients at different stages of ischemic strokeGusev EI, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2018.PubMed →
- Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex
Further reading in the lab library
Researchers also ordered
- ARA-290Erythropoietin-derived 11-residue research peptide studied in neuropathy and tissue-protection literature.
- CartalaxSynthetic peptide bioregulator studied in joint and cartilage research models.
- DihexaAngiotensin IV analog studied in synaptogenesis and HGF/c-Met receptor research.
- DSIPDelta-sleep-inducing nonapeptide studied in sleep-architecture research.